Current Reviews in Clinical and Experimental Pharmacology最新文献

{"title":"Clinical studies that initiated the use of spinal opioids for the treatment of pain: A new approach to historical review.","authors":"Igor Kissin","doi":"10.2174/2772432817666220609093243","DOIUrl":"10.2174/2772432817666220609093243","url":null,"abstract":"<p><p>Opioids administered into the spinal space by intrathecal or epidural routes can provide potent and prolonged selective analgesia. Compared to the systemic administration of opioids, spinal administration can bring about analgesia with fewer central and systemic adverse effects. For the past 40 years, spinal opioid analgesia has achieved great popularity in various fields of pain treatment. The aim of this work is to identify clinical studies that initiated the use of spinal opioids for the treatment of pain. To determine the historical role of each of the review's studies we used the combination of two factors: the study priority in terms of the time of its publication and the degree of its acknowl-edgement in the form of citation impact. The date of publication was regarded as the primary factor, but only if the count of citations indicated a sufficient acknowledgement by the other authors. The citation impact was assessed as the initial citation count - for period of five years after the year of article publication - and the total count. The selection of studies most important for the introduction of spinal opioids to clinical practice was based on two factors - the study priority in terms of the time of its publication and the degree of acknowledgement in the form of citation impact. The date of publication was regarded as the primary factor, but only if the citation count was indicative of sufficient acknowledgement by other authors. Analysis of the related data shows that the clinical studies initiating the use of spinal opioids for the treatment of pain belong to two groups of authors - Wang et al. and Behar et al. Both studies were published in 1979 and described delivery of morphine into the spinal space, although the techniques of administration were different: Wang et al. injected morphine intrathecally, Behar et al. administered morphine epidurally. The response to these studies was overwhelming -- close to a dozen reports on this topic were published in 1979 and more than a hundred - in 1980-1981. The total citation response to the Wang et al. article reached 699, and that to Behar et al. - 518. Two earlier records (1900-1901) of the use of intrathecal morphine, by Nicolae Racoviceanu-Pitesti and Otojiro Kitagawa, found no following in medical literature for more than three quarters of a century.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47546762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Drugs and Chemotherapeutic Agents on Dental Implant Osseointegration: Narrative Review.","authors":"Aida Mohammadi, Nazanin Roqani Dehkordi, Sadaf Mahmoudi, Niyousha Rafeie, Hamoun Sabri, Maryam Valizadeh, Taniya Poorsoleiman, Aryan Jafari, Alireza Mokhtari, Arshia Khanjarani, Yasaman Salimi, Melika Mokhtari, Niloofar Deravi","doi":"10.2174/2772432817666220607114559","DOIUrl":"10.2174/2772432817666220607114559","url":null,"abstract":"<p><strong>Background: </strong>Dental implants have been one of the most popular treatments for rehabilitating individuals with single missing teeth or fully edentulous jaws since their introduction. As more implant patients are well-aged and take several medications due to various systemic conditions, clinicians should be mindful of possible drug implications on bone remodeling and osseointegration.</p><p><strong>Objective: </strong>The present study aims to study and review some desirable and some unwelcomed implications of medicine on osseointegration.</p><p><strong>Methods: </strong>A broad search for proper relevant studies were conducted in four databases, including Web of Science, Pubmed, Scopus, and Google Scholar.</p><p><strong>Results: </strong>Some commonly prescribed medicines such as nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), anticoagulants, metformin, and chemotherapeutic agents may jeopardize osseointegration. On the contrary, some therapeutic agents such as anabolic, anti-catabolic, or dual anabolic and anti-catabolic agents may enhance osseointegration and increase the treatment's success rate.</p><p><strong>Conclusion: </strong>Systemic medications that enhance osseointegration include mineralization promoters and bone resorption inhibitors. On the other hand, medications often given to the elderly with systemic problems might interfere with osseointegration, leading to implant failure. However, to validate the provided research, more human studies with a higher level of evidence are required.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44905713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 Vaccination Hesitancy: A Review of the Literature and Recommendations.","authors":"Nasr Alrabadi, Shouq Bany-Melhem, Karem H Alzoubi, Osama O Alzoubi, Majd Masadeh, Sawsan Abuhammad, Sabariah Noor Harun","doi":"10.2174/2772432817666220512112913","DOIUrl":"10.2174/2772432817666220512112913","url":null,"abstract":"<p><p>Vaccines are important to improve immunity against pathogens and diseases. The current COVID-19 disease is rapidly evolving and spreading among people; therefore, it is important to utilize a proper vaccination strategy against it. Currently, many approved vaccines are available and accessible; however, there is a reported hesitancy against taking them among the public and even the health care workers. Mainly, this is attributed to the fear of the possible side effects and complications. Moreover, inaccurate knowledge disseminated through the media/social media especially by those who lack proper expertise adds confusion and more fear that affects the vaccination decision. For such reasons, it is essential to find strategies to increase the acceptability of vaccines and to enhance confidence in the vaccination process. This should be accompanied by sufficient efforts and proper clinical studies to confirm the value and the safety of the vaccines. Those strategies are important to avoid the further spread of the COVID-19 disease and to abort the pandemic worldwide, especially when considering the likely approach towards a COVID-19 booster vaccination program, in which booster vaccines are re-taken along intervals to adequately contain the rapidly evolving nature of the virus. This review article highlights the factors influencing the acceptability of the COVID-19 vaccination and enrollment in clinical trials among the public and some specific populations. Furthermore, it summarizes the suggested strategies and recommendations that can improve the attitudes towards COVID-19 vaccination programs.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43927900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Candidate for Health Promotion, Disease Prevention and Treatment, Common Rue (Ruta graveolens L.), an Important Medicinal plant in Traditional Medicine.","authors":"Mohamad Hesam Shahrajabian","doi":"10.2174/2772432817666220510143902","DOIUrl":"10.2174/2772432817666220510143902","url":null,"abstract":"<p><strong>Background: </strong>Ruta graveolens L. belongs to Rutaceae; it is a semi-wood perennial or a small evergreen sub-shrub, which is native to Southern Europe, West of Asia and Northern Africa.</p><p><strong>Objective: </strong>The goal of this manuscript was to outline the most notable traditional and modern advantages and pharmaceutical benefits of common rue.</p><p><strong>Methods: </strong>The manuscript covers review articles, randomized control experiments, analytical studies and observations, which have been gathered from different sources such as Google Scholar, Scopus, Science Direct and PubMed. A review of the literature was carried out using the keywords rutin, Ruta graveolens L., rue, common rune, coumarin, natural products and pharmaceutical benefits.</p><p><strong>Results: </strong>Rue contains quinoline alkaloids, such as graveoline and graveolinine, acridone alkaloids, such as furacridone and gravacridone, the furanoquinoline dictamnine, coumaris, such as gravelliferone, isorutarin, rutacultin, rutaretin, and suberenone, and the furanocoumarins 5-methoxypsoralen (bergapten) and 8-methoxypsoralen (xanthotoxine). Most of its aromatic and medicinal properties are from its rutin, and essential oil. It has been used in folk medicines as a stimulant, anti-inflammatory and analgesic properties, anti-androgenic activity, anti-hyperglycemic effects, anti-hyperlipidemic effects, xanthine oxidase inhibition activity, anticancer properties.</p><p><strong>Conclusion: </strong>According to pharmacological and phytochemical advantages, pennyroyal shows its importance as a medicinal plant in both modern medicinal science and traditional medicine.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49377704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of probiotics on urinary tract infections in children: A systematic review and meta-analysis.","authors":"Elham Emami, Catherine Mt Sherwin, Saeid Heidari-Soureshjani","doi":"10.2174/2772432817666220501114505","DOIUrl":"10.2174/2772432817666220501114505","url":null,"abstract":"<p><strong>Background: </strong>Urinary tract infections (UTIs) are the most prevalent bacterial infections that occur in children worldwide.</p><p><strong>Objective: </strong>This meta-analysis aims to investigate the utility of probiotics as preventive therapy in children with a UTI.</p><p><strong>Methods: </strong>The Web of Science, PubMed, and Scopus were searched for articles that investigated the relationship between probiotic consumption and the risk of UTIs. The quality of the articles was evaluated using the Jadad scale. The pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effects model. Subgroup analyses and sensitivity analyses were also conducted. The Cochran Q test and the statistic I2 were used to evaluate heterogeneity. To determine any potential publication bias, the Egger's and Begg's tests were used.</p><p><strong>Results: </strong>In total, eleven studies were selected for systematic review and meta-analysis. Compared to children who did not receive probiotics, the OR of developing or having a recurring urinary tract infection in those who received probiotics was 0.94 (95% CI; 0.88-0.999; p-value=0.046). The Begg's and Egger's tests showed no evidence of publication bias between probiotics and the risk of developing new or recurring urinary tract infections.</p><p><strong>Conclusion: </strong>Based on this systematic review and meta-analysis, probiotics could be an alternative therapy for children who are at risk of developing a UTI. They are non-pharmaceutical options and could be used as natural prophylaxis for UTIs. However, the currently published evidence does not irrefutably confirm that probiotics provide a protective effect against urinary bacterial infections. Therefore, there need to be large-scale randomized clinical trials undertaken to investigate the possible prophylaxis of probiotics.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46651236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Centricity: A Much-Needed Strategy to Enhance the Quality Use of Medicines in Older Patients.","authors":"A. Mangoni, E. Jarmuzewska","doi":"10.2174/277243281701211223100004","DOIUrl":"https://doi.org/10.2174/277243281701211223100004","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49102252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Special issue: Innovations in Early Clinical Drug Evaluation.","authors":"E. Hoogdalem, G. Bernstein","doi":"10.2174/277243281701211223102125","DOIUrl":"https://doi.org/10.2174/277243281701211223102125","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43402886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictability of Elimination and Excretion of Small Molecules in Animals and Humans, and its Impact on Dosimetry for human ADME Studies with Radiolabeled Drugs.","authors":"Ad Roffel,&nbsp;Jan Jaap van Lier,&nbsp;Gerk Rozema,&nbsp;Ewoud-Jan van Hoogdalem","doi":"10.2174/1574884716666210309103625","DOIUrl":"https://doi.org/10.2174/1574884716666210309103625","url":null,"abstract":"<p><strong>Background: </strong>We assessed the extent to which urinary and fecal excretion of <i>14</i>C-labeled drug material in animal ADME studies was predictive of human ADME studies. We compared observed plasma elimination half-lives for total drug-related radioactivity in humans to pre-study predictions, and we estimated the impact of any major differences on human dosimetry calculations.</p><p><strong>Methods: </strong>We included 34 human ADME studies with doses of <i>14</i>C above 0.1 MBq. We calculated ratios of dosimetry input parameters (percentage fecal excretion in humans <i>versus</i> animals; observed half-life in humans <i>versus</i> predicted pre-study) and output parameters (effective dose post-study <i>versus</i> pre-study) and assessed their relationship.</p><p><strong>Results: </strong>A quantitative correlation assessment did not show a statistically significant correlation between the ratios of percentages of <i>14</i>C excreted in feces and the ratios of dosimetry outcomes in the entire dataset, but a statistically significant correlation was found when assessing the studies that were based on ICRP 60/62 (n=19 studies; P=0.0028). There also appeared to be a correlation between the plasma half-life ratios and the ratios of dosimetry results. A quantitative correlation assessment showed that there was a statistically significant correlation between these ratios (P<0.0001).</p><p><strong>Conclusion: </strong>In all cases where the plasma elimination half-life for <i>14</i>C in humans was found to be longer than the predicted value, the radiation burden was still within ICRP Category IIa. Containment of the actual radiation burden below the limit of 1.00 mSv appeared to be determined partly also by our choice to limit <i>14</i>C doses to 3.7 MBq.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25466873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ventilatory Response to Hypercapnia as Experimental Model to Study Effects of Oxycodone on Respiratory Depression.","authors":"Lynn R Webster,&nbsp;Erik Hansen,&nbsp;Gregory J Stoddard,&nbsp;Austin Rynders,&nbsp;David Ostler,&nbsp;Harley Lennon","doi":"10.2174/1574884716666210225083213","DOIUrl":"https://doi.org/10.2174/1574884716666210225083213","url":null,"abstract":"<p><strong>Background: </strong>Opioid analgesics used to treat pain can cause respiratory depression. However, this effect has not been extensively studied, and life-threatening, opioid-induced respiratory depression remains difficult to predict. We tested the ventilatory response to hypercapnia for evaluating the pharmacodynamic effect of a drug on respiratory depression.</p><p><strong>Methods: </strong>We conducted a randomized, placebo-controlled, double-blind, crossover study on 12 healthy adult males. Subjects received 2 treatments (placebo and immediate-release oxycodone 30 mg) separated by a 24-hour washout period. Subjects inhaled a mixture of 7% carbon dioxide, 21% oxygen, and 72% nitrogen for 5 minutes to assess respiratory depression. Minute ventilation, respiratory rate, tidal volume, flow rate, end-tidal CO2, and oxygen saturation were recorded continuously at pre-dose and 30, 60, 120, and 180 minutes post-dose. The primary endpoint was the effect on the ventilatory response to hypercapnia at 60 minutes post-dose, as assessed by the slope of the linear relationship between minute ventilation and end-tidal CO2.</p><p><strong>Results: </strong>At 60 minutes post-dose, subjects had a mean slope of 2.4 in the oxycodone crossover period, compared to 0.1 in the placebo period (mean difference, 2.3; 95% CI: 0.2 to 4.5; p = 0.035). Statistical significance was likewise achieved at the secondary time points (30, 120, and 180 minutes post-dose, p <0.05).</p><p><strong>Conclusions: </strong>This model for testing ventilatory response to hypercapnia discriminated the effect of 30 mg of oxycodone <i>vs</i>. placebo for up to 3 hours after a single dose. It may serve as a method to predict the relative effect of a drug on respiratory depression.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25405523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between Gentamicin Administration and Ductal Patency in Very Low Birth Weight Infants.","authors":"Ufuk Cakir,&nbsp;Cuneyt Tayman","doi":"10.2174/1574884716666210603110412","DOIUrl":"https://doi.org/10.2174/1574884716666210603110412","url":null,"abstract":"<p><strong>Background: </strong>Patent Ductus Arteriosus (PDA) is associated with adverse clinical outcomes in very low birth weight (<1500g) infants.</p><p><strong>Objective: </strong>In our study, it was aimed to investigate the effect of gentamicin treatment, which is frequently used for early-onset sepsis on ductal patency.</p><p><strong>Methods: </strong>We performed a single-center retrospective review of charts of preterm infants <32 weeks gestation with birth weight <1500 grams born between June 1, 2015 and December 31, 2019 at the neonatal intensive care unit. All infants underwent an echocardiogram (ECHO) at 72 hours. To determine the effect of gentamicin treatment on hemodynamically significant PDA (hsPDA), we compared the frequency and duration of gentamicin administration between infants with hsPDA and without hsPDA.</p><p><strong>Results: </strong>During the study period, 792 patients were evaluated. Gentamicin was given to more infants with hsPDA than to those without hsPDA (89.2% vs. 64.6%, p<0.001), and the duration of therapy was longer in those infants with hsPDA (7 days vs. 9 days, p<0.001). The area under the curve for duration of gentamicin was 0.772 (%95 CI: 0.742-0.804, P=0.0001), sensitivity: 59 (%95 CI: 53-65), specificity: 82 (%95 CI: 78-88), with a cut-off day for duration of gentamicin >7 days.</p><p><strong>Conclusion: </strong>In our study, it was found that ductal contraction decreased and hsPDA rate increased as the rate and duration of gentamicin increased.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39364126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}